Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights | Zendy

Iain C. Macdougall | Zendy; Simon D. Roger | Zendy; Angel de Francisco | Zendy; David Goldsmith | Zendy; Huub Schellekens | Zendy; Hans C. Ebbers | Zendy; Wolfgang Jelkmann | Zendy; Gérard M. London | Zendy; Nicole Casadevall | Zendy; Walter H. Hörl | Zendy; D.M. Kemeny | Zendy; Carol A. Pollock | Zendy

Open Access

Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights

Author(s) -

Iain C. Macdougall,

Simon D. Roger,

Angel de Francisco,

David Goldsmith,

Huub Schellekens,

Hans C. Ebbers,

Wolfgang Jelkmann,

Gérard M. London,

Nicole Casadevall,

Walter H. Hörl,

D.M. Kemeny,

Carol A. Pollock

Publication year - 2012

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2011.500

Subject(s) - pure red cell aplasia , erythropoiesis , medicine , antibody , immunology , disease , anemia , bone marrow

Antibody-mediated pure red cell aplasia is a very rare but devastating condition affecting patients receiving treatment with erythropoiesis-stimulating agents. New cases continue to emerge, generally in clusters, consistent with an 'environmental' trigger to its pathogenesis. Defining the causes of antibody-mediated pure red cell aplasia is clearly of importance for patients with chronic kidney disease, but any developments in this area may also have relevance to other disease areas as therapeutic delivery of endogenous proteins rapidly increases. This review focuses on the current knowledge regarding the etiology of antibody-mediated pure red cell aplasia and the current approach to therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research